ADAG Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Mai 2024 @ 22:00):

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers...

Stats
Tagesvolumen	12 314.00
Durchschnittsvolumen	34 138.00
Marktkapitalisierung	123.53M
EPS	$0 ( 2024-04-02 )
Nächstes Ertragsdatum	( $-0.420 ) 2024-08-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.36
ATR14	$0.0550 (1.96%)

Adagene Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert
OZEM	-1
BWIN	-0.833

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Adagene Inc. Finanzdaten

Annual	2023
Umsatz:	$18.11M
Bruttogewinn:	$18.11M (100.00 %)
EPS:	$-0.430

FY	2023
Umsatz:	$18.11M
Bruttogewinn:	$18.11M (100.00 %)
EPS:	$-0.430

FY	2022
Umsatz:	$9.29M
Bruttogewinn:	$9.29M (100.00 %)
EPS:	$-1.850

FY	2021
Umsatz:	$10.18M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.825

Financial Reports:

No articles found.

Adagene Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Adagene Inc.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company\'s product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin\'s lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.